How The US FDA Responded To Cipla’s Dismissal Of Rescue Inhaler Complaints

Could Cipla dissuade the FDA from issuing a warning letter by defending the dismissal of thousands of complaints from asthma sufferers about jammed albuterol inhalers that came to light during a site inspection? The agency’s answer came in a warning letter.

Rescue inhaler
rescue at hand, or not • Source: Shutterstock

The complaints began rolling in after Cipla Limited began commercially manufacturing albuterol rescue inhalers for the US market in April 2020 at its plant in Pithampur, India, according to a 17 November FDA warning letter that skewered the Indian pharmaceutical company’s response to them.

Many of the complaints, which exceeded 3,000 by December 2022, were from patients whose metered dose inhalers failed to produce...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures

 
• By 

The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.

HTA Regulation: EU Publishes Guidance On Validity Of Clinical Studies For Joint Clinical Assessments

 

Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.

Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency

 

The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.

More from Compliance

HTA Regulation: EU Publishes Guidance On Validity Of Clinical Studies For Joint Clinical Assessments

 

Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By 

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.

Draft US FDA Innovative Manufacturing Strategy Takes On Global Inconsistency

 

The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.